Diagnosis and management of pulmonary hypertension over the past 100 years

Respiratory Medicine

Volumn 101, Issue 3, 2007, Pages 389-398

  van Wolferen, S A ^a   Grunberg K ^a   Vonk Noordegraaf, A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic thromboembolic pulmonary hypertension; History; Hypoxia; Left heart disease; Pulmonary hypertension

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENFLURAMINE; PHENTERMINE; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CYANOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG SYNTHESIS; DYSPNEA; ELECTROCARDIOGRAM; EMBOLISM; EPIDEMIC; FLUOROSCOPY; HEART CATHETERIZATION; HEART DISEASE; HUMAN; HYPOXIA; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; THORAX RADIOGRAPHY; THROMBOSIS; VEIN OCCLUSION;

ANOXIA; APPETITE DEPRESSANTS; DISEASE OUTBREAKS; HEART DISEASES; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; HYPERTENSION, PULMONARY; LUNG; PULMONARY EMBOLISM;

EID: 33846696717     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.11.022     Document Type: Article

References (113)

1. Brenner O. The lungs in heart disease. Br J Tuberc Dis Chest 51 (1957) 209-222
2. Klob. Wien Wochenbl 31 (1865) 45
3. Romberg E. Über sklerose der lungen arterie. Dtsch Arch Klin Med 48 (1891) 197-206
4. Mönckeberg J.G. Über die genuine arteriosklerose der lungenarterie. Dtsch Med Wochenschr 33 (1907) 1243-1246
5. Arrillaga F.C. Sclérose de l'artère pulmonaire secondaire à certains états pulmonaires chroniques (cardiaques noirs). Arch Mal Coeur 6 (1913) 518-529
6. Arrilaga F.C. Sclérose de l'artère pulmonaire secondaire (cardiaques noirs). Bull Mém Soc Méd Hôp Paris 48 3rd series (1924) 292-303
7. Brachetto-Brian D. Concepto anatomo-pathologico de los cardiacos engross de Ayerza. Rev Soc Med Int Soc Tisiol 1 (1925) 821-931
8. Posselt A. Zur pathologie und klinik der primären atherosklerosis pulmonalis. Arch Intern Med 11 (1925) 357-398
9. Brenner O. Pathology of the vessels of the pulmonary circulation. Arch Intern Med 56 (1935) 211-237 457-97, 724-52, 976-1014, 1190-1241
10. Brill I.C., and Krygier C.K. Primary pulmonary vascular sclerosis. Arch Intern Med 68 (1941) 560-577
11. Larrabee W.F., Parker R.L., and Edwards J.E. Pathology of intrapulmonary arteries and arterioles in mitral stenosis. Proc Mayo Clin 24 (1949) 316-326
12. Simonneau G., Galie N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
13. Forssmann W. Die Sondierung des rechten Herzens. Klin Wochnschr 8 (1929) 2085-2087
14. Cournand A. Pulmonary circulation: its control in man with some remarks on methodology. Science 125 (1957) 1231-1235
15. Richards D.W. Right heart catheterisation: its contributions to physiology and medicine. Science 125 (1957) 1181-1185
16. Kanemoto N., Furuya H., Etoh T., Sasamoto H., and Matsuyama S. Chest roentgenograms in primary pulmonary hypertension. Chest 76 (1979) 45-49
17. Rich S., Pietra G.G., Kieras K., Hart K., and Brundage B.H. Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. Ann Intern Med 105 (1986) 499-502
18. Woodruff W.W., Hoeck B.E., Chitwood W.R., Lyerly H.K., Sabiston Jr. D.C., and Chen J.T. Radiographic findings in pulmonary hypertension from unresolved embolism. AJR 144 (1985) 681-686
19. Satoh T., Kyotani S., Okano Y., Nakanishi N., and Kunieda T. Descriptive patterns of severe chronic pulmonary hypertension by chest radiography. Respir Med 99 (2005) 329-336
20. Bossone E., Paciocco G., Iarussi D., et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 121 (2002) 513-518
21. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 25 (2004) 2243-2278
22. Gurtner H.P. Ätiologie und Häufigkeit der primär vaskulären Formen des chronischen Cor pulmonale. Dtsch Med Wochenschr 94 (1969) 850
23. Kay J.M., Smith P., and Heath D. Aminorex and the pulmonary circulation. Thorax 26 (1971) 262-270
24. Abenhaim L., Moride Y., Brenot F., et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335 (1996) 609-616
25. Mark E.J., Patalas E.D., Chang H.T., Evans R.J., and Kessler S.C. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 337 (1997) 602-606
26. Wagenvoort C.A. Pathology of pulmonary hypertension (1977), Wiley, New York, NY p. 111-5
27. Rothman R.B., Ayestas M.A., Dersch C.M., and Baumann M.H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: implications for primary pulmonary hypertension. Circulation 100 (1999) 869-875
28. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
29. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
30. Fuster V., Steele P.M., Edwards W.D., Gersh B.J., McGoon M.D., and Frye R.L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70 (1984) 580-587
31. International PPH Consortium. Heterozygous germline mutations in BMPR2, encoding a TGF-ß receptor, cause familial primary pulmonary hypertension. Nat Genet 26 (2000) 81-84
32. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
33. Thomson J.R., Machado R.D., Pauciulo M.W., et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-ß family. J Med Genet 37 (2000) 741-745
34. Cogan J.D., Pauciulo M.W., Batchman A.P., et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 174 (2006) 590-598
35. Eddahibi S., Humbert M., Fadel E., et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108 (2001) 1141-1150
36. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 (2004) 25S-32S
37. McMurtry I.F., Davidson A.B., Reeves J.T., and Grover R.F. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 38 (1976) 99-104
38. Rich S., and Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension. Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76 (1987) 135-141
39. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
40. Sitbon O., Humbert M., Jais X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
41. Higenbottam T., Wheeldon D., Wells F., and Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1 (1984) 1046-1047
42. Moncada S., Gryglewski R., Bunting S., and Vane J.R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263 (1976) 663-665
43. Hyman A.L., Chapnick B.M., Kadowitz P.J., et al. Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids. Proc Natl Acad Sci USA 74 (1977) 5711-5715
44. Christman B., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
45. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
46. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-302
47. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
48. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
49. Liu C., Liu K., Ji Z., and Liu G. Treatments for pulmonary arterial hypertension. Respir Med 100 (2006) 765-774
50. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
51. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
52. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
53. Barst R.J., Langleben D., Frost A., et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) 441-447
54. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 47 (2006) 2049-2056
55. McLaughlin V.V., Sitbon O., Badesch D.B., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
56. Atz A.M., and Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 91 (1999) 307-310
57. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
58. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
59. Gilmour J.R., and Evans W. Primary pulmonary hypertension. J Pathol Bacteriol 58 (1946) 687-697
60. Smith P., Heath D., Yacoub M.H., Madden B., Caslin A., and Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 160 (1990) 111-121
61. Yi E.S., Kim H., Ahn H., et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 162 (2000) 1577-1586
62. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., and Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927-934
63. Stenmark K.R., Davie N.J., Reeves J.T., and Frid M.G. Hypoxia, leukocytes, and the pulmonary circulation. J Appl Physiol 98 (2005) 715-721
64. Cool C.D., Kennedy D., Voelkel N.F., and Tuder R.M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28 (1997) 434-442
65. Olsen E.G.J. Perivascular fibrosis in mitral valve disease. A possible mechanism of production. Br J Dis Chest 60 (1966) 129-136
66. Wagenvoort C.A. Morphologic changes in the intrapulmonary veins. Hum Pathol 1 (1970) 205-213
67. Wagenvoort C.A. Morphological substrate for the reversibility and irreversibility of pulmonary hypertension. Eur Heart J 9 Suppl. J (1988) 7-12
68. Moller J.E., Hillis G.S., Oh J.K., and Pellikka P.A. Prognostic importance of secondary pulmonary hypertension after acute myocardial infarction. Am J Cardiol 96 (2005) 199-203
69. Von Euler U.S., and Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand 12 (1946) 301-320
70. Motley H.L., Cournand A., Werko L., Himmelstein A., and Dresdale D. The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man. Am J Physiol 150 (1947-1948) 315-320
71. Peirson R.E., and Jensen R. Brisket disease. In: Fincher M.G., Gibbons W.J., Mayer K., and Park S.E. (Eds). Diseases of cattle (1956), American Veterinary Publications, Evanston, IL
72. Canepa A., Chavez R., Hurtado A., Rotta A., and Velasquez T. Pulmonary circulation at sea level and at high altitude. J Appl Physiol 9 (1956) 328-336
73. Alexander A.F., Will D.H., Grover R.F., and Reeves J.T. Pulmonary hypertension and right ventricular hypertrophy in cattle at high altitude. Am J Vet Res 20 (1960) 199-204
74. Reeves J.T., and Grover R.F. Insights by Peruvian scientists into the pathogenesis of human chronic hypoxic pulmonary hypertension. J Appl Physiol 98 (2005) 384-389
75. Wagenvoort C.A., and Wagenvoort N. Hypoxic pulmonary vascular lesions in man at high altitude and in patients with chronic respiratory disease. Pathol Microbiol 39 (1973) 276
76. Wagenvoort C.A., and Wagenvoort N. Pulmonary venous changes in chronic hypoxia. Virchows Arch A 372 (1976) 51-56
77. Weir E.K., Lopez-Barneo J., Buckler K.J., and Archer S.L. Acute oxygen-sensing mechanisms. N Engl J Med 353 (2005) 2042-2055
78. 2+ channels. High Alt Med Biol 6 (2005) 133-146
79. Doi M., Nakano K., Hiramoto T., and Kohno N. Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxemia. Respir Med 97 (2003) 915-920
80. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 93 (1980) 391-398
81. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1 (1981) 681-686
82. Wright J.L., Levy R.D., and Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 60 (2005) 605-609
83. Owen W.R., Thomas W.A., Castleman B., and Bland E.F. Unrecognised emboli to the lungs with subsequent cor pulmonale. N Engl J Med 249 (1953) 919-926
84. Fedullo P.F., Auger W.R., Channick R.N., Kerr K.M., and Rubin L.J. Chronic thromboembolic pulmonary hypertension. Clin Chest Med 16 (1995) 353-374
85. Pengo V., Lensing A.W., Prins M.H., et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350 (2004) 2257-2264
86. Moser K.M., and Braunwald N.S. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest 64 (1973) 29-35
87. Jamieson S.W., Kapelanski D.P., Sakakibara N., et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Sur 76 (2003) 1457-1462 [discussion 1462-54]
88. Ghofrani H.A., Schermuly R.T., Rose F., et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167 (2003) 1139-1141
89. Bresser P., Fedullo P.F., Auger W.R., et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 23 (2004) 595-600
90. Hoeper M.M., Kramm T., Wilkens H., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2363-2367
91. Bonderman D., Nowotny R., Skoro-Sajer N., et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 128 (2005) 2599-2603
92. Hughes R., George P., Parameshwar J., et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 60 (2005) 707
93. Hughes R.J., Jais X., Bonderman D., et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 28 (2006) 138-143
94. Lang I., Gomez-Sanchez M., Kneussl M., et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129 (2006) 1636-1643
95. Vizza C.D., Badagliacca R., Sciomer S., et al. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. Cardiology 106 (2006) 168-173
96. Peacock A., Naeije R., Galie N., and Reeves T. End points in pulmonary arterial hypertension: the way forward. Eur Respir J 23 (2004) 947-953
97. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 43 (2004) 48S-55S
98. Johnson R.A., and Rubin L.J. Noninvasive evaluation of right ventricular function. Clin Chest Med 8 (1987) 65-80
99. Vonk-Noordegraaf A., van Wolferen S.A., Marcus J.T., Boonstra A., Postmus P.E., Peeters J.W., et al. Noninvasive assessment and monitoring of the pulmonary circulation. Eur Respir J 25 (2005) 758-766
100. Prasad N., Lang C.C., McAlpine H.M., et al. Raised plasma concentrations of brain natriuretic peptide in pulmonary arterial hypertension. Respir Med 89 (1995) 445-447
101. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 31 (1998) 202-208
102. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
103. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 (2003) 735-740
104. Mukerjee D., Yap L.B., Holmes A.M., et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97 (2003) 1230-1236
105. Mukerjee D., St George D., Knight C., et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43 (2004) 461-466
106. Lewczuk J., Ajlan A.W., Piszko P., Jagas J., Mikulewicz M., and Wrabec K. Electrocardiographic signs of right ventricular overload in patients who underwent pulmonary embolism event(s). Are they useful in diagnosis of chronic thromboembolic pulmonary hypertension?. J Electrocardiol 37 (2004) 219-225
107. Merklinger S.L., Jones P.L., Martinez E.C., and Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112 (2005) 423-431
108. Schermuly R.T., Dony E., Grofrani H.A., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115 (2005) 2811-2821
109. Ghofrani H.A., Seeger W., and Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 353 (2005) 1412-1413
110. Nagaoka T., Fagan K.A., Gebbs S.A., et al. Inhaled rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171 (2005) 494-499
111. Guignabert C., Raffestin B., Benferhat R., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111 (2005) 2812-2819
112. McMurtry M.S., Archer S.L., Altieri D.C., et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115 (2005) 1479-1491
113. Zhao Y.D., Courtman D.W., Deng Y., Kugathasan L., Zhang Q., and Stewart D.J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 (2005) 442-450